Monoclonal Antibodies Against B-Cell Chronic Lymphocytic Leukemia (B-CLL) Tumors
Background:
The National Cancer Institute's Experimental Transplantation and
Immunology Branch is seeking statements of capability or interest
from parties interested in collaborative research to further
develop, evaluate, or commercialize diagnostic or therapeutic mAbs
against B-CLL tumor cells.
Technology:
B-cell chronic lymphocytic leukemia (B-CLL) is an incurable disease
developed by more than 15,000 Americans each year. Currently, there
are no therapeutic monoclonal antibodies (mAbs) that specifically
recognize B-CLL tumor cells. Receptor tyrosine kinase-like
orphan receptor 1 (ROR1) is a constitutively expressed
tumor-specific cell surface antigen and an ideal target for
therapeutic antibodies.
This invention describes four mouse anti-human ROR1 mAbs
(hybridomas designated 2A2, 2D11, 1A1, and 1A7). All four
mAbs bind specifically to the extracellular domain of human ROR1
and have good potential for therapeutic development by either
humanization, conversion to chimeric mouse/human antibodies, or
conjugation to a radioisotope, chemical drug or bacterial
toxin. This technology can also be used for the development
of research tools for the study of ROR1 in cancer biology.
Further R&D Needed:
- Evaluate anti-tumor activity of anti-human ROR1 mAbs in ex vivo
and in vivo B-CLL models
- Evaluate diagnostic capability of anti-human ROR1 mAbs in the
detection of untreated, refractory, or relapsed B-CLL
R&D Status:
- MAbs are being characterized and compared with respect to
affinity, specificity, and epitope
- MAbs are being used to discover other ROR1-expressing
cancers
IP Status: Research Tool.
Patent protection is not being pursued for this technology.
Value Proposition:
- Ability to develop diagnostic or therapeutic antibodies against
ROR1-expressing cancers such as B-CLL and other hematologic and
solid malignancies
- Ability to develop research tools for the study of ROR1 in
cancer biology
Contact Information:
John D. Hewes, Ph.D.
NCI Technology Transfer Center
Tel: 301-435-3121
Email: hewesj@mail.nih.gov
Please reference advertisement #796
Revised 1/16/2008
This opportunity is also listed under the following categories: